The Role of BTK Inhibition in the Treatment of Chronic Lymphocytic Leukemia: A Clinical View

References

• Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66. doi:10.3322/canjclin.57.1.43
   PubMed Web of Science ®Google Scholar
• Freymann JG, Vander JB, Marler EA, Meyer DG. Prolonged corticosteroid therapy of chronic lymphocytic leukaemia and the closely allied malignant lymphomas. Br J Haematol. 1960;6:303–323. doi:10.1111/j.1365-2141.1960.tb06247.x
   PubMed Web of Science ®Google Scholar
• CLL Trialists’ Collaborative Group. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. J Natl Cancer Inst. 1999;91:861–868.
   PubMed Web of Science ®Google Scholar
• Callea V, Brugiatelli M, Stelitano C, et al. Incidence of second neoplasia in patients with B-cell chronic lymphocytic leukemia treated with chlorambucil maintenance chemotherapy. Leuk Lymphoma. 2006;47:2314–2320. doi:10.1080/10428190600880977
   PubMed Web of Science ®Google Scholar
• Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000;343:1750–1757. doi:10.1056/nejm200012143432402
   PubMed Web of Science ®Google Scholar
• Johnson S, Smith AG, Löffler H, et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. Lancet. 1996. doi:10.1016/s0140-6736(96)91681-5
   Web of Science ®Google Scholar
• Niederle N, Megdenberg D, Balleisen L, et al. Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia. Ann Hematol. 2013;92:653–660. doi:10.1007/s00277-012-1660-6
   PubMed Web of Science ®Google Scholar
• Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009;27:4378–4384. doi:10.1200/JCO.2008.20.8389
   PubMed Web of Science ®Google Scholar
• Hagemeister F. Rituximab for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs. 2010;70:261–272. doi:10.2165/11532180-000000000-00000
   PubMed Web of Science ®Google Scholar
• Bauer K, Rancea M, Roloff V, et al. Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia. Cochrane Database Syst Rev. 2012. doi:10.1002/14651858.CD008079.pub2
   Web of Science ®Google Scholar
• Cartron G, de Guibert S, Dilhuydy M-S, et al. Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study. Blood. 2014;124:2196–2202. doi:10.1182/blood-2014-07-586610
   PubMed Web of Science ®Google Scholar
• Wierda W, O’Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4070–4078. doi:10.1200/JCO.2005.12.516
   PubMed Web of Science ®Google Scholar
• Tam CS, O’Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008;112:975–980. doi:10.1182/blood-2008-02-140582
   PubMed Web of Science ®Google Scholar
• Robak T, Moiseev SI, Dmoszynska A, et al. Rituximab, fludarabine, and cyclophosphamide (R-FC) prolongs progression free survival in relapsed or refractory chronic lymphocytic leukemia (CLL) compared with FC alone: final results from the international randomized phase III REACH trial. Blood. 2008;112:lba–1. doi:10.1182/blood.v112.11.lba-1.lba-1
   Google Scholar
• Fischer K, Bahlo J, Fink AM, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016;127:208–215. doi:10.1182/blood-2015-06-651125
   PubMed Web of Science ®Google Scholar
• Eichhorst B, Fink A-M, Bahlo J, et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016;17:928–942. doi:10.1016/S1470-2045(16)30051-1
   PubMed Web of Science ®Google Scholar
• Dal Porto JM, Gauld SB, Merrell KT, Mills D, Pugh-Bernard AE, Cambier J. B cell antigen receptor signaling 101. Mol Immunol. 2004;41:599–613. doi:10.1016/j.molimm.2004.04.008
   PubMed Web of Science ®Google Scholar
• Pal Singh S, Dammeijer F, Hendriks RW. Role of Bruton’s tyrosine kinase in B cells and malignancies. Mol Cancer. 2018. doi:10.1186/s12943-018-0779-z
   Web of Science ®Google Scholar
• Liang C, Tian D, Ren X, et al. The development of Bruton’s tyrosine kinase (BTK) inhibitors from 2012 to 2017: a mini-review. Eur J Med Chem. 2018;151:315–326. doi:10.1016/j.ejmech.2018.03.062
   PubMed Web of Science ®Google Scholar
• Swinney DC. The role of binding kinetics in therapeutically useful drug action. Curr Opin Drug Discov Devel. 2009;12:31–39.
   PubMed Web of Science ®Google Scholar
• Kaptein A, de Bruin G, Emmelot-van Hoek M, et al. Potency and selectivity of BTK inhibitors in clinical development for B-cell malignancies. Blood. 2018;132:1871. doi:10.1182/blood-2018-99-109973
   PubMed Web of Science ®Google Scholar
• Kaur V, Swami A. Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib. Ann Hematol. 2017;96:1175–1184. doi:10.1007/s00277-017-2973-2
   PubMed Web of Science ®Google Scholar
• Burger JA. Bruton’s tyrosine kinase (BTK) inhibitors in clinical trials. Curr Hematol Malig Rep. 2014;9:44–49. doi:10.1007/s11899-013-0188-8
   PubMed Web of Science ®Google Scholar
• Bond DA, Woyach JA. Targeting BTK in CLL: beyond ibrutinib. Curr Hematol Malig Rep. 2019;14:197–205. doi:10.1007/s11899-019-00512-0
   PubMed Web of Science ®Google Scholar
• Atkinson BT, Ellmeier W, Watson SP. Tec regulates platelet activation by GPVI in the absence of Btk. Blood. 2003;102:3592–3599. doi:10.1182/blood-2003-04-1142
   PubMed Web of Science ®Google Scholar
• Leong DP, Caron F, Hillis C, et al. The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. Blood. 2016;128:138–140. doi:10.1182/blood-2016-05-712828
   PubMed Web of Science ®Google Scholar
• Cheng C, Woronow D, Nayernama A, Wroblewski T, Jones SC. Ibrutinib-associated ventricular arrhythmia in the FDA adverse event reporting system. Leuk Lymphoma. 2018;59:3016–3017. doi:10.1080/10428194.2018.1457149
   PubMed Web of Science ®Google Scholar
• McMullen JR, Boey EJH, Ooi JYY, et al. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood. 2014;124:3829–3830. doi:10.1182/blood-2014-10-604272
   PubMed Web of Science ®Google Scholar
• Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32–42. doi:10.1056/nejmoa1215637
   PubMed Web of Science ®Google Scholar
• Barr PM, Brown JR, Hillmen P, et al. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. Blood. 2017;129:2612–2615. doi:10.1182/blood-2016-12-737346
   PubMed Web of Science ®Google Scholar
• Chen LS, Bose P, Cruz ND, et al. A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. Blood. 2018. doi:10.1182/blood-2018-06-860593
   Web of Science ®Google Scholar
• Sun C, Nierman P, Kendall EK, et al. Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib. Blood. 2020;136:93–105. doi:10.1182/blood.2019003715
   PubMed Web of Science ®Google Scholar
• Bose P, Gandhi VV, Keating MJ. Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses. Expert Opin Drug Metab Toxicol. 2016;12:1381–1392. doi:10.1080/17425255.2016.1239717
   PubMed Web of Science ®Google Scholar
• Kriegsmann K, Kriegsmann M, Witzens-Harig M. Acalabrutinib, A second-generation bruton’s tyrosine kinase inhibitor. Recent Results Cancer Res. 2018. doi:10.1007/978-3-319-91439-8_14
   Google Scholar
• Mu S, Tang Z, Novotny W, et al. Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton’s tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects. Cancer Chemother Pharmacol. 2020;85:391–399. doi:10.1007/s00280-019-04015-w
   PubMed Web of Science ®Google Scholar
• Dhillon S. Tirabrutinib: first approval. Drugs. 2020. doi:10.1007/s40265-020-01318-8
   Web of Science ®Google Scholar
• Li Y, Ramírez-Valle F, Xue Y, et al. Population pharmacokinetics and exposure response assessment of CC-292, a potent BTK inhibitor, in patients with chronic lymphocytic leukemia. J Clin Pharmacol. 2017;57:1279–1289. doi:10.1002/jcph.923
   Web of Science ®Google Scholar
• Novero A, Ravella PM, Chen Y, Dous G, Liu D. Ibrutinib for B cell malignancies. Exp Hematol Oncol. 2014;3. doi:10.1186/2162-3619-3-4.
   Google Scholar
• De Claro RA, McGinn KM, Verdun N, et al. FDA approval: ibrutinib for patients with previously treated mantle cell lymphoma and previously treated chronic lymphocytic leukemia. Clin Cancer Res. 2015;21:3586–3590. doi:10.1158/1078-0432.CCR-14-2225
   PubMed Web of Science ®Google Scholar
• O’Brien S, Jones JA, Coutre SE, et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016;17:1409–1418. doi:10.1016/S1470-2045(16)30212-1
   PubMed Web of Science ®Google Scholar
• Zenz T, Mohr J, Edelmann J, et al. Treatment resistance in chronic lymphocytic leukemia - the role of the p53 pathway. Leuk Lymphoma. 2009;50:510–513. doi:10.1080/10428190902763533
   PubMed Web of Science ®Google Scholar
• Byrd JC, Harrington B, O’Brien S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:323–332. doi:10.1056/nejmoa1509981
   PubMed Web of Science ®Google Scholar
• Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373:2425–2437. doi:10.1056/nejmoa1509388
   PubMed Web of Science ®Google Scholar
• Moreno C, Greil R, Demirkan F, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:43–56. doi:10.1016/S1470-2045(18)30788-5
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Wang XV, Kay NE, et al. Ibrutinib–rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381:432–443. doi:10.1056/nejmoa1817073
   PubMed Web of Science ®Google Scholar
• Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379:2517–2528. doi:10.1056/nejmoa1812836
   PubMed Web of Science ®Google Scholar
• Sharman JP, Banerji V, Fogliatto LM, et al. ELEVATE TN: phase 3 study of acalabrutinib combined with obinutuzumab (O) or alone vs O plus chlorambucil (Clb) in patients (Pts) with treatment-naive chronic lymphocytic leukemia (CLL). Blood. 2019;134:31. doi:10.1182/blood-2019-128404
   Web of Science ®Google Scholar
• Munir T, Brown JR, O’Brien S, et al. Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94:1353–1363. doi:10.1002/ajh.25638
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Cramer P, Demirkan F, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016;17:200–211. doi:10.1016/S1470-2045(15)00465-9
   PubMed Web of Science ®Google Scholar
• Ghia P, Pluta A, Wach M, et al. Ascend: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2020;38:2849–2861. doi:10.1200/JCO.19.03355
   PubMed Web of Science ®Google Scholar
• O’Brien S, Furman RR, Coutre S, et al. Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood. 2018;131:1910–1919. doi:10.1182/blood-2017-10-810044
   PubMed Web of Science ®Google Scholar
• Byrd JC, Wierda WG, Schuh A, et al. Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. Blood. 2020;135:1204–1213. doi:10.1182/blood.2018884940
   PubMed Web of Science ®Google Scholar
• Furman RR, Cheng S, Lu P, et al. Ibrutinib resistance in chronic lymphocytic leukemia. N Engl J Med. 2014. doi:10.1056/nejmc1402716
   Web of Science ®Google Scholar
• Woyach JA, Furman RR, Liu T-M, et al. Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014;370:2286–2294. doi:10.1056/nejmoa1400029
   PubMed Web of Science ®Google Scholar
• Nishida M, Sugimoto K, Hara Y, et al. Amplification of receptor signalling by Ca2+ entry-mediated translocation and activation of PLCγ2 in B lymphocytes. EMBO J. 2003;22:4677–4688. doi:10.1093/emboj/cdg457
   Web of Science ®Google Scholar
• Allan JN, Furman RR. Current trends in the management of Richter’s syndrome. Int J Hematol Oncol. 2018;7:IJH09. doi:10.2217/ijh-2018-0010
   Google Scholar
• Master S, Leary C, Takalkar A, et al. Successful treatment of Richter transformation with ibrutinib in a patient with chronic lymphocytic leukemia following allogeneic hematopoietic stem cell transplant. Case Rep Oncol. 2017;10:534–541. doi:10.1159/000477338
   PubMed Web of Science ®Google Scholar
• Fischer A, Bastian S, Cogliatti S, et al. Ibrutinib-induced rapid response in chemotherapy-refractory Richter’s syndrome. Hematol Oncol. 2018;36:370–371. doi:10.1002/hon.2464
   PubMed Web of Science ®Google Scholar
• Hillmen P, Schuh A, Eyre TA, et al. Acalabrutinib monotherapy in patients with Richter transformation from the phase 1/2 ACE-CL-001 clinical study. Blood. 2016;128:60. doi:10.1182/blood.v128.22.60.60
   PubMed Web of Science ®Google Scholar
• Younes A, Brody J, Carpio C, et al. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study. Lancet Haematol. 2019;6:e67–e78. doi:10.1016/S2352-3026(18)30217-5
   PubMed Web of Science ®Google Scholar
• Mikudina B, Goodall M, Adler AI. NICE guidance on ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia in the presence of 17p deletion or TP53 mutation. Lancet Oncol. 2017;18:289–290. doi:10.1016/S1470-2045(17)30062-1
   Web of Science ®Google Scholar
• Sinha R, Redekop WK. Cost-effectiveness of ibrutinib compared with obinutuzumab with chlorambucil in untreated chronic lymphocytic leukemia patients with comorbidities in the United Kingdom. Clin Lymphoma Myeloma Leuk. 2018;18:e131–e142. doi:10.1016/j.clml.2017.12.005
   PubMed Web of Science ®Google Scholar
• Barnes JI, Divi V, Begaye A, et al. Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p. Blood Adv. 2018;2:1946–1956. doi:10.1182/bloodadvances.2017015461
   PubMed Web of Science ®Google Scholar
• Harkins RA, Patel SP, Flowers CR. Cost-effectiveness of new targeted agents in the treatment of chronic lymphocytic leukemia. Cancer J. 2019. doi:10.1097/PPO.0000000000000411
   Web of Science ®Google Scholar
• Chang BY, Huang M, Francesco M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res Ther. 2011;13:R115. doi:10.1186/ar3400
   PubMed Web of Science ®Google Scholar
• Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA. 2010;107:13075–13080. doi:10.1073/pnas.1004594107
   PubMed Web of Science ®Google Scholar
• Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013;122:2539–2549. doi:10.1182/blood-2013-06-507947
   PubMed Web of Science ®Google Scholar
• Allen JL, Tata PV, Fore MS, et al. Increased BCR responsiveness in B cells from patients with chronic GVHD. Blood. 2014;123:2108–2115. doi:10.1182/blood-2013-10-533562
   PubMed Web of Science ®Google Scholar
• Dubovsky JA, Flynn R, Du J, et al. Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. J Clin Invest. 2014;4867–4876. doi:10.1172/JCI75328.
   Web of Science ®Google Scholar
• Baldoni S, Ruggeri L, Del Papa B, et al. NOTCH1 inhibition prevents GvHD and maintains GvL effect in murine models. Bone Marrow Transplant. 2021;56:2019–2023. doi:10.1038/s41409-021-01297-8
   Web of Science ®Google Scholar
• DelPapa B, Baldoni S, Dorillo E, et al. Decreased NOTch1 activation correlates with response to ibrutinib in chronic lymphocytic leukemia. Clin Cancer Res. 2019;25:7540–7553. doi:10.1158/1078-0432.CCR-19-1009
   Web of Science ®Google Scholar
• Miklos D, Cutler CS, Arora M, et al. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood. 2017;130:2243–2250. doi:10.1182/blood-2017-07-793786
   PubMed Web of Science ®Google Scholar
• Volmering S, Block H, Boras M, Lowell CA, Zarbock A. The neutrophil Btk signalosome regulates integrin activation during sterile inflammation. Immunity. 2016;44:73–87. doi:10.1016/j.immuni.2015.11.011
   PubMed Web of Science ®Google Scholar
• Al-Harbi NO, Nadeem A, Ahmad SF, et al. Therapeutic treatment with Ibrutinib attenuates imiquimod-induced psoriasis-like inflammation in mice through downregulation of oxidative and inflammatory mediators in neutrophils and dendritic cells. Eur J Pharmacol. 2020;877:173088. doi:10.1016/j.ejphar.2020.173088
   PubMed Web of Science ®Google Scholar
• Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565–574. doi:10.1016/S0140-6736(20)30251-8
   PubMed Web of Science ®Google Scholar
• Guan W, Ni Z-Y, Hu Y, et al. Clinical characteristics of Coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–1720. doi:10.1056/nejmoa2002032
   PubMed Web of Science ®Google Scholar
• Mondal S, Quintili AL, Karamchandani K, Bose S. Thromboembolic disease in COVID-19 patients: a brief narrative review. J Intens Care. 2020;8. doi:10.1186/s40560-020-00483-y.
   Web of Science ®Google Scholar
• Conti P, Ronconi G, Caraffa AL, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020. doi:10.23812/CONTI-E
   Web of Science ®Google Scholar
• Florence JM, Krupa A, Booshehri LM, Davis SA, Matthay MA, Kurdowska AK. Inhibiting bruton’s tyrosine kinase rescues mice from lethal influenza-induced acute lung injury. Am J Physiol. 2018. doi:10.1152/ajplung.00047.2018
   Web of Science ®Google Scholar
• Roschewski M, Lionakis MS, Sharman JP, et al. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Sci Immunol. 2020;5:eabd0110. doi:10.1126/SCIIMMUNOL.ABD0110
   PubMed Web of Science ®Google Scholar
• Treon SP, Castillo JJ, Skarbnik AP, et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19 infected patients. Blood. 2020;135:1912–1915. doi:10.1182/BLOOD.2020006288
   PubMed Web of Science ®Google Scholar
• NCT. Acalabrutinib study with best supportive care versus best supportive care in subjects hospitalized with COVID-19. CALAVI (Calquence Against the Virus); 2020. Available from: https://clinicaltrials.gov/show/NCT04346199. Accessed October 8, 2021.
   Google Scholar
• Scarfò L, Chatzikonstantinou T, Rigolin GM, et al. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia. 2020;34:2354–2363. doi:10.1038/s41375-020-0959-x
   PubMed Web of Science ®Google Scholar
• Mato AR, Roeker LE, Lamanna N, et al. Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood. 2020;136:1134–1143. doi:10.1182/blood.2020006965
   PubMed Web of Science ®Google Scholar
• Herishanu Y, Avivi I, Aharon A, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137:3165–3173. doi:10.1182/blood.2021011568
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Sander S, Bullinger L, et al. Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. Haematologica. 2007;92:1242–1245. doi:10.3324/haematol.10720
   PubMed Web of Science ®Google Scholar
• Ahn IE, Tian X, Ipe D, et al. Prediction of outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: development and validation of a four-factor prognostic model. J Clin Oncol. 2021;39:576–585. doi:10.1200/JCO.20.00979
   PubMed Web of Science ®Google Scholar
• Marschitz I, Tinhofer I, Hittmair A, et al. Analysis of Bcl-2 protein expression in chronic lymphocytic leukemia: a comparison of three semiquantitation techniques. Am J Clin Pathol. 2000;113:219–229. doi:10.1309/491w-l1tn-ufqx-t61b
   PubMed Web of Science ®Google Scholar
• Jones JA, Mato AR, Wierda WG, et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018;19:65–75. doi:10.1016/S1470-2045(17)30909-9
   PubMed Web of Science ®Google Scholar
• Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax–rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378:1107–1120. doi:10.1056/nejmoa1713976
   PubMed Web of Science ®Google Scholar
• Mato AR, Hill BT, Lamanna N, et al. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients. Ann Oncol. 2017;28:1050–1056. doi:10.1093/annonc/mdx031
   PubMed Web of Science ®Google Scholar
• Brandhuber B, Gomez E, Smith S, et al. LOXO-305, a next generation reversible BTK inhibitor, for overcoming acquired resistance to irreversible BTK inhibitors. Clin Lymphoma Myeloma Leuk. 2018. doi:10.1016/j.clml.2018.07.081
   Web of Science ®Google Scholar
• Mato AR, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021;397:892–901. doi:10.1016/S0140-6736(21)00224-5
   PubMed Web of Science ®Google Scholar
• Reiff SD, Mantel R, Smith LL, et al. The btk inhibitor arq 531 targets ibrutinib-resistant cll and Richter transformation. Cancer Discov. 2018;8:1300–1315. doi:10.1158/2159-8290.CD-17-1409
   PubMed Web of Science ®Google Scholar
• Woyach J, Stephens DM, Flinn IW, et al. Final results of phase 1, dose escalation study evaluating ARQ 531 in patients with relapsed or refractory B-cell lymphoid malignancies. Blood. 2019;134:4298. doi:10.1182/blood-2019-127260
   Web of Science ®Google Scholar
• Katewa A, Wang Y, Hackney JA, et al. Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell-associated damage in IFNα-driven lupus nephritis. JCI Insight. 2017;2. doi:10.1172/jci.insight.90111
   Web of Science ®Google Scholar
• Chan P, Yu J, Chinn L, et al. Population pharmacokinetics, efficacy exposure-response analysis, and model-based meta-analysis of fenebrutinib in subjects with rheumatoid arthritis. Pharm Res. 2020. doi:10.1007/s11095-019-2752-y
   Web of Science ®Google Scholar
• Byrd JC, Smith S, Wagner-Johnston N, et al. First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. Oncotarget. 2018;9:13023–13035. doi:10.18632/oncotarget.24310
   PubMedGoogle Scholar
• Fabian CA, Reiff SD, Guinn D, et al. Abstract 1207: SNS-062 demonstrates efficacy in chronic lymphocytic leukemia in vitro and inhibits C481S mutated Bruton tyrosine kinase. Cancer Res. 2017. doi:10.1158/1538-7445.am2017-1207
   Web of Science ®Google Scholar
• Ciechanover A, Orian A, Schwartz AL. Ubiquitin-mediated proteolysis: biological regulation via destruction. BioEssays. 2000;22:442–451. doi:10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q
   PubMed Web of Science ®Google Scholar
• Pickart CM. Mechanisms underlying ubiquitination. Annu Rev Biochem. 2001;70:503–533. doi:10.1146/annurev.biochem.70.1.503
   PubMed Web of Science ®Google Scholar
• Sun Y, Zhao X, Ding N, et al. PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies. Cell Res. 2018;28:779–781. doi:10.1038/s41422-018-0055-1
   PubMed Web of Science ®Google Scholar
• Huang HT, Dobrovolsky D, Paulk J, et al. A chemoproteomic approach to query the degradable kinome using a multi-kinase degrader. Cell Chem Biol. 2018;25:88–99.e6. doi:10.1016/j.chembiol.2017.10.005
   PubMed Web of Science ®Google Scholar
• Dobrovolsky D, Wang ES, Morrow S, et al. Bruton tyrosine kinase degradation as a therapeutic strategy for cancer. Blood. 2019;133:952–961. doi:10.1182/blood-2018-07-862953
   Web of Science ®Google Scholar
• Buhimschi AD, Armstrong HA, Toure M, et al. Targeting the C481S ibrutinib-resistance mutation in Bruton’s tyrosine kinase using PROTAC-mediated degradation. Biochemistry. 2018;57:3564–3575. doi:10.1021/acs.biochem.8b00391
   PubMed Web of Science ®Google Scholar
• Sun Y, Ding N, Song Y, et al. Degradation of Bruton’s tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas. Leukemia. 2019;33:2105–2110. doi:10.1038/s41375-019-0440-x
   PubMed Web of Science ®Google Scholar
• Robbins DW, Kelly A, Tan M, et al. Nx-2127, a degrader of BTK and IMiD neosubstrates, for the treatment of B-cell malignancies. Blood. 2020;136:34. doi:10.1182/blood-2020-141461
   Web of Science ®Google Scholar
• Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17:768–778. doi:10.1016/S1470-2045(16)30019-5
   PubMed Web of Science ®Google Scholar
• Jain P, Keating M, Wierda W, et al. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood. 2015. doi:10.1182/blood-2014-09-603670
   Web of Science ®Google Scholar
• Hillmen P, Rawstron AC, Brock K, et al. Ibrutinib plus venetoclax in relapsed/refractory chronic lymphocytic leukemia: the CLARITY study. J Clin Oncol. 2019;37:2722–2729. doi:10.1200/JCO.19.00894
   PubMed Web of Science ®Google Scholar
• Aw A, Brown JR. The potential combination of BCL-2 inhibitors and ibrutinib as frontline therapy in chronic lymphocytic leukemia. Leuk Lymphoma. 2017;58:2287–2297. doi:10.1080/10428194.2017.1312387
   PubMed Web of Science ®Google Scholar